StockIQpro
NASDAQ:TPST

Tempest Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Tempest Therapeutics, Inc. reported net income of −$26.3M in fiscal 2025. Free cash flow was −$26.8M, and the diluted share count rose 93.3%.Summary generated from Tempest Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 30, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−203.6%
Debt / equityn/a
Free cash flow−$26.8M
FCF marginn/a
Share count change+93.3%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−27−35−29−42−27
Net income−28−36−29−42−26
Free cash flow−26−32−28−33−27

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations